Catalyst Pharmaceuticals, Inc.CPRXNASDAQ
Loading
Operating Cash Flow Growth AcceleratingAccelerating
Percentile Rank77
5Y CAGR+21.6%
Year-over-Year Change
Year-over-year operating cash flow growth rate
5Y CAGR
+21.6%/yr
Long-term compound
Percentile
P77
Within normal range
vs 5Y Ago
2.7x
Strong expansion
Streak
1 qtr
Consecutive growthAccelerating
| Period | Value |
|---|---|
| Q4 2025 | 38.39% |
| Q3 2025 | -54.50% |
| Q2 2025 | 18.74% |
| Q1 2025 | -15.29% |
| Q4 2024 | -2.74% |
| Q3 2024 | 13.62% |
| Q2 2024 | 100.89% |
| Q1 2024 | -42.63% |
| Q4 2023 | 23.31% |
| Q3 2023 | 46.74% |
| Q2 2023 | 154.80% |
| Q1 2023 | -69.88% |
| Q4 2022 | -2.96% |
| Q3 2022 | 57.69% |
| Q2 2022 | 208.93% |
| Q1 2022 | -55.79% |
| Q4 2021 | -11.66% |
| Q3 2021 | 38.48% |
| Q2 2021 | 310.99% |
| Q1 2021 | -70.90% |
| Q4 2020 | 14.45% |
| Q3 2020 | -13.67% |
| Q2 2020 | 83.90% |
| Q1 2020 | -41.32% |
| Q4 2019 | -24.42% |
| Q3 2019 | 15.99% |
| Q2 2019 | 276.07% |
| Q1 2019 | 4.22% |
| Q4 2018 | -22.20% |
| Q3 2018 | -50.96% |
| Q2 2018 | 25.90% |
| Q1 2018 | -50.91% |
| Q4 2017 | -53.06% |
| Q3 2017 | 17.75% |
| Q2 2017 | 17.48% |
| Q1 2017 | 12.08% |
| Q4 2016 | -34.59% |
| Q3 2016 | 24.53% |
| Q2 2016 | 26.76% |
| Q1 2016 | -28.05% |